1887

Abstract

Hepatitis C virus (HCV) infection is prevalent throughout the world and interferon (IFN)-based treatments are currently the only therapeutic option. However, depending upon variations in their human leukocyte antigen (HLA), some patients do not respond well to IFN therapy. The current study evaluated the HLA allele and haplotype distribution of 204 HCV-seropositive individuals from Islamabad, Pakistan, who were receiving standard IFN therapy. In this cohort, 150 patients (74 %) showed a sustained virological response to IFN therapy, whereas 54 (26 %) did not. In addition to the HCV patients, 102 unrelated healthy volunteers were used as controls. DNA was isolated from the blood of the patients and controls for HLA-DRB1 and HLA-DQB1 allele typing, whilst plasma was used for HCV detection and genotyping. HLA-DRB1*04 was found to impart a significant protective advantage [Bonferroni-corrected value (pc)=0.047] against HCV infection. In patients on IFN therapy, HLA-DRB1*11 and -DQB1*0301 (pc=0.044) were found to be associated with viral clearance. In contrast, HLA-DRB1*07 (pc=0.008) individually or in combination with HLA-DQB1*02 was found to be associated with viral persistence. These associations of HLA with HCV persistence or clearance will be beneficial in deciding the therapeutic regimen for Pakistani patients infected with HCV genotype 3a.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.018119-0
2010-08-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/91/8/1931.html?itemId=/content/journal/jgv/10.1099/vir.0.018119-0&mimeType=html&fmt=ahah

References

  1. Aikawa T., Kojima M., Onishi H., Tamura R., Fukuda S., Suzuki T., Tsuda F., Okamoto H., Miyakawa Y. other authors 1996; HLA DRB1 and DQB1 alleles and haplotypes influencing the progression of hepatitis C. J Med Virol 49:274–278
    [Google Scholar]
  2. Alric L., Izopet J., Fort M., Vinel J. P., Fontenelle P., Orfila C., Payen J. L., Sandres K., Desmorat H. other authors 1999; Study of the association between major histocompatibility complex class II genes and the response to interferon alpha in patients with chronic hepatitis C infection. Hum Immunol 60:516–523
    [Google Scholar]
  3. Asti M., Martinetti M., Zavaglia C., Cuccia M. C., Gusberti L., Tinelli C., Cividini A., Bruno S., Salvaneschi L. other authors 1999; Human leukocyte antigen class II and III alleles and severity of hepatitis C virus-related chronic liver disease. Hepatology 29:1272–1279
    [Google Scholar]
  4. Bunce M., O'Neill C. M., Barnardo M. C., Krausa P., Browning M. J., Morris P. J., Welsh K. I. 1995; Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 46:355–367
    [Google Scholar]
  5. Corghi D. B., Gonçales N. S., Marques S. B., Gonçales F. L. Jr 2008; Distribution of the human leukocyte antigen class II alleles in Brazilian patients with chronic hepatitis C virus infection. Braz J Med Biol Res 41:884–889
    [Google Scholar]
  6. Correa P. A., Whitworth W. C., Kuffner T., McNicholl J., Anaya J. M. 2002; HLA-DR and DQB1 gene polymorphism in the north-western Colombian population. Tissue Antigens 59:436–439
    [Google Scholar]
  7. Cramp M. E., Carucci P., Underhill J., Naoumov N. V., Williams R., Donaldson P. T. 1998; Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia. J Hepatol 29:207–213
    [Google Scholar]
  8. Cursino-Santos J. R., Donadi E. A., Martinelli A. L., Louzada-Junior P., Martinez-Rossi N. M. 2007; Evolution of hepatitis C virus infection under host factor influence in an ethically complex population. Liver Int 27:1371–1378
    [Google Scholar]
  9. El-Chennawi F. A., Auf F. A., Metwally S. S., Mosaad Y. M., El-Wahab M. A., Tawhid Z. E. 2008; HLA-class II alleles in Egyptian patients with hepatocellular carcinoma. Immunol Invest 37:661–674
    [Google Scholar]
  10. Fanning L. J., Levis J., Kenny-Walsh E., Wynne F., Whelton M., Shanahan F. 2000; Viral clearance in hepatitis C (1b) infection: relationship with human leukocyte antigen class II in a homogeneous population. Hepatology 31:1334–1337
    [Google Scholar]
  11. Fanning L. J., Levis J., Kenny-Walsh E., Whelton M., O'Sullivan K., Shanahan F. 2001; HLA class II genes determine the natural variance of hepatitis C viral load. Hepatology 33:224–230
    [Google Scholar]
  12. Fanning L. J., Kenny-Walsh E., Shanahan F. 2004; Persistence of hepatitis C virus in a white population: associations with human leukocyte antigens class I. Hum Immunol 65:745–751
    [Google Scholar]
  13. García-Sastre A., Biron C. A. 2006; Type 1 interferons and the virus–host relationship: a lesson in détente. Science 312:879–882
    [Google Scholar]
  14. Ge D., Fellay J., Thompson A. J., Simon J. S., Shianna K. V., Urban T. J., Heinzen E. L., Qiu P., Bertelsen A. H. other authors 2009; Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399–401
    [Google Scholar]
  15. Harcourt G., Hellier S., Bunce M., Satsangi J., Collier J., Chapman R., Phillips R., Klenerman P. 2001; Effect of HLA class II genotype on T helper lymphocyte responses and viral control in hepatitis C virus infection. J Viral Hepat 8:174–179
    [Google Scholar]
  16. Hnatyszyn H. J. 2005; Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Antivir Ther 10:1–11
    [Google Scholar]
  17. Hohler T., Gerken G., Notghi A., Knolle P., Lubjuhn R., Taheri H., Schneider P. M., Meyer zum Buschenfelde K. H., Rittner C. 1997; MHC class II genes influence the susceptibility to chronic active hepatitis C. J Hepatol 27:259–264
    [Google Scholar]
  18. Hong X., Yu R. B., Sun N. X., Wang B., Xu Y. C., Wu G. L. 2005; Human leukocyte antigen class II DQB1*0301, DRB1*1101 alleles and spontaneous clearance of hepatitis C virus infection: a meta-analysis. World J Gastroenterol 11:7302–7307
    [Google Scholar]
  19. Hue S., Cacoub P., Renou C., Halfon P., Thibault V., Charlotte F., Picon M., Rifflet H., Piette J. other authors 2002; Human leukocyte antigen class II alleles may contribute to the severity of hepatitis C virus-related liver disease. J Infect Dis 186:106–109
    [Google Scholar]
  20. Idrees M., Riazuddin S. 2008; Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. BMC Infect Dis 8:69
    [Google Scholar]
  21. Iminishi T., Akaza T., Kimura A., Tokunaga K., Gojobori T. 1992; Estimation of allele and haplotype frequencies for HLA and complement loci. In HLA 1991: Proceedings of the Eleventh International Histocompatibility Workshop and Conference vol I pp 76–79 Edited by Tsuji K., Aizawa M., Sasazuki. Oxford: Oxford University Press;
    [Google Scholar]
  22. Jiao J., Wang J. B. 2005; Hepatitis C virus genotypes, HLA-DRB alleles and their response to interferon- α and ribavirin in patients with chronic hepatitis C. Hepatobiliary Pancreat Dis Int 4:80–83
    [Google Scholar]
  23. Kamal S. M., Fehr J., Roesler B., Peters T., Rasenack J. W. 2002; Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 123:1070–1083
    [Google Scholar]
  24. Kikuchi I., Ueda A., Mihara K., Miyanaga O., Machidori H., Ishikawa E., Tamura K. 1998; The effect of HLA alleles on response to interferon therapy in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 10:859–863
    [Google Scholar]
  25. Kryczka W., Brojer E., Kalinska A., Urbaniak A., Zarebska-Michaluk D. 2001; DRB1 alleles in relation to severity of liver disease in patients with chronic hepatitis C. Med Sci Monit 7:Suppl. 1217–220
    [Google Scholar]
  26. Ksiaa L., Ayed-Jendoubi S., Sfar I., Gorgi Y., Najjar H. A., Abdallah T. B., Ayed K. 2007; Clearance and persistence of hepatitis C virus in a Tunisian population: association with HLA class I and class II. Viral Immunol 20:312–319
    [Google Scholar]
  27. Kuzushita N., Hayashi N., Moribe T., Katayama K., Kanto T., Nakatani S., Kaneshige T., Tatsumi T., Ito A. other authors 1998; Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus. Hepatology 27:240–244
    [Google Scholar]
  28. Lloyd A. R., Jagger E., Post J. J., Crooks L.-A., Rawlinson W. D., Hahn Y. S., Ffrench R. A. 2007; Host and viral factors in the immunopathogenesis of primary hepatitis C virus infection. Immunol Cell Biol 85:24–32
    [Google Scholar]
  29. López-Vázquez A., Rodrigo L., Miña-Blanco A., Martínez-Borra J., Fuentes D., Rodríguez M., Pérez R., González S., López-Larrea C. 2004; Extended human leukocyte antigen haplotype EH18.1 influences progression to hepatocellular carcinoma in patients with hepatitis C virus infection. J Infect Dis 189:957–963
    [Google Scholar]
  30. Mangia A., Gentile R., Cascavilla I., Margaglione M., Villani M. R., Stella F., Modola G., Agostiano V., Gaudiano C., Andriulli A. 1999; HLA class II favors clearance of HCV infection and progression of the chronic liver damage. J Hepatol 30:984–989
    [Google Scholar]
  31. McKiernan S. M., Hagan R., Curry M., McDonald G. S., Kelly A., Nolan N., Walsh A., Hegarty J., Lawlor E., Kelleher D. 2004; Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology 40:108–114
    [Google Scholar]
  32. Minton E. J., Smillie D., Neal K. R., Irving W. L., Underwood J. C., James V. 1998; Association between MHC class II alleles and clearance of circulating hepatitis C virus. Members of the Trent Hepatitis C Virus Study Group. J Infect Dis 178:39–44
    [Google Scholar]
  33. Nascimbeni M., Mizukoshi E., Bosmann M., Major M. E., Mihalik K., Rice C. M., Feinstone S. M., Rehermann B. 2003; Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol 77:4781–4793
    [Google Scholar]
  34. Ohno O., Mizokami M., Wu R. R., Saleh M. G., Ohba K., Orito E., Mukaide M., Williams R., Lau J. Y. 1997; New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a. 1b, 2a, 2b, 3a, 3b, 4:5a– and 6a J Clin Microbiol 35:201–207
    [Google Scholar]
  35. Qamar R., Ayub Q., Mohyuddin A., Helgason A., Mazhar K., Mansoor A., Zerjal T., Tyler-Smith C., Mehdi S. Q. 2002; Y chromosomal DNA variation in Pakistan. Am J Hum Genet 70:1107–1124
    [Google Scholar]
  36. Raja N. S., Janjua K. A. 2008; Epidemiology of hepatitis C virus infection in Pakistan. J Microbiol Immunol Infect 41:4–8
    [Google Scholar]
  37. Reich D., Thangaraj K., Patterson N., Price A. L., Singh L. 2009; Reconstructing Indian population history. Nature 461:489–494
    [Google Scholar]
  38. Roe D. L., Lewis R. E., Cruse J. M. 2000; Association of HLA-DQ and -DR alleles with protection from or infection with HIV-1. Exp Mol Pathol 68:21–28
    [Google Scholar]
  39. Sadler A. J., Williams B. R. 2008; Interferon-inducible antiviral effectors. Nat Rev Immunol 8:559–568
    [Google Scholar]
  40. Sambrook J., Fritsch E. F., Maniatis T. 1989 Molecular Cloning: a Laboratory Manual , 2nd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory;
  41. Scotto G., Fazio V., D'Alessandro G., Monno L., Saracino A., Palumbo E., Angarano G. 2003; Association between HLA class II antigens and hepatitis C virus infection. J Biol Regul Homeost Agents 17:316–321
    [Google Scholar]
  42. Singh R., Kaul R., Kaul A., Khan K. 2007; A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol 13:1770–1787
    [Google Scholar]
  43. Sinn D. H., Paik S. W., Kang P., Kil J. S., Park S. U., Lee S. Y., Song S. M., Gwak G. Y., Choi M. S. other authors 2008; Disease progression and the risk factor analysis for chronic hepatitis C. Liver Int 28:1363–1369
    [Google Scholar]
  44. Thio C. L., Thomas D. L., Goedert J. J., Vlahov D., Nelson K. E., Hilgartner M. W., O'Brien S. J., Karacki P., Marti D. other authors 2001; Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis 184:16–21
    [Google Scholar]
  45. Thursz M., Yallop R., Goldin R., Trepo C., Thomas H. C. 1999; Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet 354:2119–2124
    [Google Scholar]
  46. Tillmann H. L., Chen D. F., Trautwein C., Kliem V., Grundey A., Berning-Haag A., Boker K., Kubicka S., Pastucha L. other authors 2001; Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease. Gut 48:714–718
    [Google Scholar]
  47. Vejbaesya S., Songsivilai S., Tanwandee T., Rachaibun S., Chantangpol R., Dharakul T. 2000; HLA association with hepatitis C virus infection. Hum Immunol 61:348–353
    [Google Scholar]
  48. Wang L. Y., Lin H. H., Lee T. D., Wu Y. F., Hu C. T., Cheng M. L., Lo S. Y. 2005; Human leukocyte antigen phenotypes and hepatitis C viral load. J Clin Virol 32:144–150
    [Google Scholar]
  49. Yee L. J. 2004; Host genetic determinants in hepatitis C virus infection. Genes Immun 5:237–245
    [Google Scholar]
  50. Yenigün A., Durupinar B. 2002; Decreased frequency of the HLA-DRB1*11 allele in patients with chronic hepatitis C virus infection. J Virol 76:1787–1789
    [Google Scholar]
  51. Yoon S. K., Han J. Y., Pyo C. W., Yang J. M., Jang J. W., Kim C. W., Chang U. I., Bae S. H., Choi J. Y. other authors 2005; Association between human leukocytes antigen alleles and chronic hepatitis C virus infection in the Korean population. Liver Int 25:1122–1127
    [Google Scholar]
  52. Yoshizawa K., Ota M., Saito S., Maruyama A., Yamaura T., Rokuhara A., Orii K., Ichijo T., Matsumoto A. other authors 2003; Long-term follow-up of hepatitis C virus infection: HLA class II loci influences the natural history of the disease. Tissue Antigens 61:159–165
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.018119-0
Loading
/content/journal/jgv/10.1099/vir.0.018119-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error